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Background: Treatment delay is an important prognostic factor for patients with acute ST-elevation myocardial
infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). We aimed to determine recent
trends in these delays and factors associated with longer delays.
Methods: We compared two datasets collected in Helsinki University Central Hospital in 2007–2008 (HUS-STEMI I)
and 2011–2012 (HUS-STEMI II), a total of 500 patients treated with primary PCI within 12 hours of the onset of
symptoms.
Results: Delays of the emergency medical system (EMS) were longer in HUS-STEMI I than II (medians 81 vs. 67 min,
respectively, p < 0.001). Although door-to-balloon times were longer in the later dataset (33 vs. 48 min, p < 0.001)
most of the patients (75.3% vs. 62.8%, respectively, p = 0.010) were treated within the recommendation (<60 min)
of the European Society of Cardiology (ESC). In HUS-STEMI II, patient arrival at the hospital during off-hours was
associated with longer door-to-balloon time (40 and 57.5 min, p = 0.001) and system delay (111 and 127 min,
p = 0.009). However, in HUS-STEMI I, arrival time did not impact the delays. Longer system delay was associated
with higher mortality rates.
Conclusions: Though the delays inside the hospital have increased they are still mostly within the ESC guidelines.
Still, only about half of the patients are treated within a system delay of recommended two hours. Albeit our results
are good in comparison with previous studies, further efforts for decreasing the delays particularly within the EMS
should be established.
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Treatment delaysBackground
Total ischemic time is a significant predictor of outcome
in patients with acute ST-elevation myocardial infarction
(STEMI) [1-3]. Timely reperfusion therapy reduces mor-
tality of patients with STEMI [1,4-7]. According to inter-
national guidelines, primary percutaneous coronary
intervention (PCI) is the primary choice of reperfusion
therapy if PCI can be performed by an experienced team
and within two hours of first medical contact (FMC)* Correspondence: tuomo.nieminen@iki.fi
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unless otherwise stated.[8,9]. In addition, the overall risk of the patient should
be considered when choosing the reperfusion method
[10]. Delay between the onset of symptoms and reperfu-
sion therapy reflects the total ischemic time which is why
the delay should be reduced as much as possible. How-
ever, reperfusion therapy inside the time limits of the
international guidelines is seldom achieved in a majority
of hospitals [11-13]. Although some earlier studies have
reported significant decreases in door-to-balloon times
over years, most of the latest studies have only shown
limited improvement in treatment delays [11,12,14-16].
Previous studies have also indicated that the delays are
longer during off-hours than during regular office hours
[15,17,18].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2261/14/115The objective of this study was to determine the delays
for STEMI patients treated with primary PCI in the
Helsinki University Central Hospital (HUCH), providing
24/7 PCI-service and being responsible for all primary
PCIs in the hospital district of Helsinki and Uusimaa
(HUS) in southern Finland. We compared two different
datasets, HUS-STEMI I collected in 2007–2008 and
HUS-STEMI II in 2011–2012, in order to determine
whether there has been any improvement in delays within
the last years. In addition, we assessed the variation in the
delays between regular and off-hours. Finally, we deter-




The STEMI patients for the earlier dataset, HUS-STEMI
I, were enrolled between June 13, 2007 and June 12,
2008 in the HUS area [19]. Patients were included if they
had STEMI and lived permanently in the HUS district.
They also had to give a written consent. The criteria for
STEMI were symptoms of acute myocardial ischemia
and ECG showing at least 2 mm ST-elevation (1.5 mm
for women) in at least two of the leads V1-V3 or at least
1 mm ST-elevation in other two adjacent leads (in leads
V4-6, V8, V4R, I, aVL, II, III and aVF) or a new left bun-
dle branch block (LBBB). To ensure complete coverage
hospital files were also searched to find all additional
STEMI patients treated in the HUS area during this time
period. The patients who had not been recruited during
their hospital stay were contacted later by letters and
phone calls. The HUS-STEMI I dataset also included
176 patients treated with fibrinolysis and 78 patients
who did not receive any primary reperfusion therapy;
these were excluded from the present study.
The other dataset, HUS-STEMI II, comprises of all the
STEMI patients treated with primary PCI in HUCH
between January 1, 2011 and April 30, 2012. Patients were
collected prospectively to a local STEMI-registry to deter-
mine the safety and efficacy of a new antithrombotic drug
combination, enoxaparine-prasugrel-bivalirudin, intro-
duced in the local STEMI treatment guidelines in the
HUS area in autumn 2010. To be included patients had to
meet the same criteria for STEMI as in the earlier dataset
and be treated with primary PCI within 12 hours from the
onset of pain. Patients treated with fibrinolysis were not
included in the data. Eighty-one patients were excluded
from the present study because they did not live perman-
ently in the HUS area.
The primary PCI patients in HUS-STEMI I received
aspirin 250 mg p.o, enoxaparine 30 mg i.v, abciximab
bolus 0.25 mg/kg i.v. (or alternatively eptifibatide or tiro-
fiban) and clopidogrel 600 mg p.o. According to the new
local guidelines, the patients in the HUS-STEMI IIdataset were to receive aspirin 250 mg p.o, enoxaparine
30 mg i.v. and prasugrel 60 mg p.o. upon FMC, and an
infusion of bivalirudin in the course of PCI.
The final cohorts included 194 patients from HUS-
STEMI I and 306 patients from HUS-STEMI II. Regard-
less of their differences, the two datasets are comparable.
They both contain all STEMI patients treated with pri-
mary PCI in HUCH during the data collection period. In
addition, the registration of data points was essentially
similar.
The study was performed in accordance with the
Declaration of Helsinki. The collection of HUS-STEMI I
dataset was approved by the ethical board of the HUCH
district, and the patients gave the informed consent to
participate in the study. The HUS-STEMI II is a registry
study, which does not need an ethical approval from the
above-mentioned board. However, we received the
appropriate approval needed for the registry study as well
as the overall approval from our institution to perform
the study.
Guidelines for delays and definitions for time points
Patient delay is the delay from the onset of symptoms to
FMC. The time from FMC to the arrival at hospital con-
stitutes the delay of the emergency medical system
(EMS). The system delay refers to the sum of the EMS
delay and door-to-balloon time within the hospital. The
PCI time point was defined as the first balloon inflation.
The total ischemic time is the sum of the patient delay
and the system delay. We concentrated on the system
delay and its components because it is more easily affected
by organizational changes such as changes in EMS or hos-
pital strategies. Patient delay can also be affected by recall
bias meaning that a patient might be uncertain about the
time of the onset of symptoms. According to the latest
guidelines stated by the European Society of Cardiology
(ESC) the system delay for primary PCI should be less
than 90 minutes and for high-risk patients (early pre-
senters within 2 hours or large anterior infarcts) less than
60 minutes. Door-to-balloon time in PCI-capable hospi-
tals should be less than 60 minutes [8].
The time points for the assessment of delays used in
this study were the onset of symptoms, first diagnostic
ECG (considered as FMC), arrival at PCI providing
HUCH hospital (Meilahti), the beginning of angiography
and PCI. From these parameters, the patient delay, the
delay of EMS, door-to-balloon time, the system delay
and the overall delay were calculated.
The arrival time at the hospital was divided to groups
based on whether patient arrived during regular or off-
hours in order to determine whether there was variation
between the time groups. The definition for off-hours
used in this study was weekdays between 4 pm and
7 am, weekends and national holidays.
Table 1 Baseline characteristics for both datasets
HUS-STEMI I HUS-STEMI II
n = 194 n = 306
% % p
Mean age, mean (SD) years 64.8 (12.9) 64.3 (14.0) 0.920
Age > 75 years 23.7 26.1 0.542
Male sex 64.9 69.0 0.352
Diabetes 15.5 19.6 0.240
Current smoker 35.6 39.0 0.449
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http://www.biomedcentral.com/1471-2261/14/115The patient outcomes measured in this study were 90-
day all-cause mortality and major adverse cardiac event
(MACE) within 90 days of the initial STEMI. The
composite of MACE consisted of cardiovascular death,
non-fatal myocardial infarction, ischemic or hemorrhagic
stroke and unplanned new target vessel or non-target ves-
sel revascularization. Myocardial infarction was defined
according to current international guidelines [20]. Stroke
was defined as any focal neurological deficit of ischemic
or hemorrhagic origin lasting for longer than 24 hours.Hypertension 63.4 53.3 0.026
Dyslipidemia 44.8 41.5 0.462
Renal dysfunction 1.5 4.2 0.094
AMI 18.6 10.8 0.014
Stroke 8.8 6.5 0.354
CABG 4.1 5.2 0.573
PCI 9.8 13.4 0.227
ASA 23.2 26.8 0.367
P2Y12 inhibitor 2.1 3.9 0.250
Warfarin 9.3 8.8 0.863
Anterior infarct 46.8 53.6 0.143
Killip class 2–4 12.4 18.0 0.096
Admission at regular hours 41.5 40.8 0.888
Values are percentages with the exception of age.
AMI, acute myocardial infarction; ASA, acetosalicylic acid; CABG, coronary artery
bypass graft; PCI, percutaneous coronary intervention.Statistical analysis
Continuous data was expressed as median with inter-
quartile range (IQR) and categorical data as percentages.
Percentage of patients treated within the time limits rec-
ommended by ESC was calculated. Mann–Whitney U
and χ2 tests were used for continuous and categorical vari-
ables, respectively. A linear regression analysis was used to
evaluate the significance of factors possibly related to lon-
ger treatment delays. These factors included patient base-
line characteristics, prior cardiovascular diseases, Killip
class, hospital arrival time and patient related delay. In
HUS-STEMI II we also analyzed whether there was a cor-
relation between the delays and adherence to the new
local guidelines (enoxaparine, prasugrel and bivalirudine).
The delays and relationships were compared between the
two datasets. A logistic regression analysis was used for
binary covariates such as endpoints. P < 0.05 was consid-
ered statistically significant. Statistical analysis was per-
formed with SPSS 15.0 (SPSS, Inc., Chicago, IL).Results
A total of 500 patients were included in the analysis
(Table 1). HUS-STEMI I had more patients with prior
diagnosed hypertension or prior acute myocardial infarc-
tion (AMI). Otherwise the baseline characteristics for
the datasets were similar. In addition, if each dataset was
divided into groups based on hospital arrival in regular
compared to off-hours, the two groups were similar with
one exception: there were more patients with a previous
stroke during off-hours in HUS-STEMI I.Changes in delays
The median EMS delay was longer in HUS-STEMI I than
II (81 vs. 67 min, respectively, p < 0.001) (Figure 1). How-
ever, the median door-to-balloon time was longer in HUS-
STEMI II than I (48 vs. 33 min, respectively, p < 0.001)
with total system delays being virtually the same in both
datasets (119.5 vs. 119 min, respectively, p = 0.549).
There were no significant changes in the patient delays
or the total ischemic times, although the delays were nu-
merically slightly longer in HUS-STEMI II.Guideline adherence
Recommendations for treatment delays were quite
poorly achieved in both HUS-STEMI I and II (Table 2).
System delay was less than 90 minutes in only approxi-
mately one fourth of the cases. System delay of less than
120 minutes was achieved in a half of the cases; the dif-
ferences between datasets were not statistically signifi-
cant. Regarding the achievement of the target time
frame of 60 minutes for EMS delay, a clear improvement
was seen between the datasets. In HUS-STEMI II 41.0%
of patients achieved the target time frame as opposed to
24.7% in HUS-STEMI I. The delays inside the hospital
were more often within the recommended time limits
(<60 min) in both datasets (Table 2).
Factors associated with delays
In HUS-STEMI I, previous myocardial infarction was as-
sociated with shorter EMS delay (Table 3) and previous
stroke with longer EMS delay. In addition, if patient re-
lated delay was more than 2 hours, the system delay was
also longer.
In HUS-STEMI II, patient arrival at hospital during
off-hours was strongly associated with longer system
delay and door-to-balloon time (Tables 3 and 4). Patients
treated according to the new antithrombotic medication
Figure 1 Median delays (min) with inter-quartile ranges.
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http://www.biomedcentral.com/1471-2261/14/115protocol had shorter system delays and EMS delays.
Treatment according to new guidelines had no effect on
the door-to-balloon time. In addition, Killip class 2–4,
when admitted to the hospital, was associated with lon-
ger door-to-balloon time in adjusted but not in un-
adjusted logistic regression.
The EMS delay was significantly longer in HUS-
STEMI I than II during both on- and off-hours. On the
other hand, the door-to-balloon time was longer in
HUS-STEMI II during off-hours.Treatment delays and prognosis
There was no significant difference in the incidence of
MACE or death within 90 days between the datasets.
The occurrence of MACE was numerically slightly
smaller in HUS-STEMI I than II but this was not statis-
tically significant (11.4% and 14.9%, respectively, p =
0.252). Mortality in HUS-STEMI I and II was 10.5% and
10.8%, respectively (p = 0.897).Table 2 Guideline adherence: proportion of the delays
within the recommended time limits
Delay HUS-STEMI I HUS-STEMI II
% % p
Patient delay <120 min 55.8 50.8 0.290
EMS delay <60 min 24.7 41.0 <0.001
Door-to-balloon time <60 min 75.3 62.8 0.010
System delay <90 min 22.0 25.0 0.499
System delay <120 min 52.0 50.4 0.761
Time limit recommendations by the European Society of Cardiology (ESC).
EMS, emergency medical system.Longer door-to-balloon time (>60 min) and longer sys-
tem delay (>90 min) were the only time delay factors
that had any effect on the incidence of MACE within
90 days after the STEMI. In unadjusted analysis, 7.9% of
the patients with a door-to-balloon time less than 60 mi-
nutes had a MACE within 90 days of the STEMI com-
pared to 15.7% of the patients with longer than 60 min
door-to-balloon time (p = 0.018). The median door-to-
balloon time for patients who had a MACE within
90 days was 60 minutes as opposed to 41 minutes in
those without MACE (p = 0.028). Of the patients treated
within the system delay of 90 minutes 2.2% had a MACE
within 90 days compared to 13.1% for the patients with
system delay over 90 minutes (p = 0.003). However, only
the association between the system delay and 90-day
MACE was statistically significant in regression analysis
adjusted to baseline characteristics.
In unadjusted analysis, age (p < 0.001), previous AMI
(p = 0.005), previous stroke (p = 0.029), diabetes (p =
0.001), Killip class 2–4 (p < 0.001) were other factors that
had a link with 90-day MACE. When adjusted to baseline
characteristics, only diabetes and Killip 2–4 were associ-
ated with higher incidence of 90-day MACE along with
system delay.
Regarding the 90-day mortality, patient related delay
was the only time delay factor that had a link with the
mortality: in the surviving patient group the median pa-
tient related delay was 116 minutes as opposed to
67.5 minutes in the other group (p = 0.044). Yet, this
correlation was not statistically significant when adjusted
to baseline characteristics.
Other factors associated with 90-day mortality when
analyzed individually were age (p < 0.001), sex (p =
Table 3 Association of patient characteristics to the delays in multivariable linear regression
HUS-STEMI I HUS-STEMI II
EMS delay Door-to-balloon System delay EMS delay Door-to-balloon System delay
Beta p Beta p Beta p Beta p Beta p Beta p
Age 0.082 0.394 0.132 0.235 0.139 0.184 −0.007 0.915 −0.028 0.705 −0.039 0.596
Sex −0.048 0.564 −0.073 0.445 −0.034 0.709 −0.036 0.555 0.010 0.884 0.008 0.899
Smoking 0.095 0.308 0.112 0.295 0.169 0.096 −0.085 0.192 0.019 0.788 −0.050 0.489
Post-MI −0.198 0.025 0.058 0.566 −0.163 0.091 0.089 0.166 0.047 0.497 0.090 0.193
Post-stroke 0.184 0.030 −0.059 0.545 0.164 0.073 −0.072 0.250 −0.066 0.331 −0.089 0.188
Diabetes 0.152 0.058 0.070 0.459 0.134 0.134 −0.064 0.316 0.003 0.966 −0.003 0.963
Hypertension −0.048 0.565 −0.002 0.987 −0.046 0.612 0.037 0.586 −0.076 0.295 −0.084 0.248
Dyslipidemia −0.034 0.686 0.097 0.317 0.032 0.725 −0.012 0.851 0.174 0.016 0.149 0.038
Anterior infarct −0.092 0.235 −0.028 0.753 −0.026 0.761 0.047 0.433 −0.014 0.831 0.026 0.689
Killip class 2–4 −0.126 0.116 −0.056 0.541 −0.084 0.327 −0.052 0.404 0.141 0.039 0.073 0.278
Regular hours −0.102 0.202 −0.003 0.974 −0.097 0.260 −0.011 0.851 −0.204 0.002 −0.167 0.010
Patient related delay > 120 min 0.215 0.101 0.059 0.702 0.321 0.027 0.159 0.099 0.017 0.877 0.063 0.556
New treatment protocol −0.178 0.003 −0.089 0.174 −0.18 0.006
The new treatment protocol in the HUS-STEMI II dataset refers to the use of antithrombotic drug combination enoxaparine-prasugrel-bivalirudin.
MI, myocardial infarction.
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0.001), diabetes (p = 0.001) and Killip class 2–4 (p <
0.001). When adjusted to baseline characteristics, only age
(p = 0.001), previous stroke (p = 0.027), diabetes (p =




The unexpected finding in this study was that door-to-
balloon times were longer in 2011–2012 than 2007–
2008. On the other hand, the EMS delays had become
shorter in the course of years, although still being essen-
tially longer than the in-hospital delays. As the system
delay consists of the EMS delay and the delay inside the
hospital, the related changes obliterated each other and
the system delays between the compared datasets were
similar.
Even though the in-hospital delay was longer in the
latter than in the earlier dataset, both groups achievedTable 4 Median delays (inter-quartile range) in regular vs. off
HUS-STEMI I
Regular hours Off-hours
n = 72 n = 108
Patient delay 113 (41–246) 109 (42–221)
EMS delay 83 (60–112) 80 (62–121)
Door-to-balloon time 37 (25–63) 31 (21–60)
System delay 120.5 (92–152) 118.5 (92–174)
Total ischemic time 227.5 (161–398) 255 (159–429)
EMS, emergency medical system.the guidelines for door-to-balloon times quite well and
the local delays are short in international comparison.
Although being 15 minutes longer than in the earlier
dataset, the median door-to-balloon time of 48 minutes
in HUS-STEMI II is clearly within the recommendation
of 60 minutes [8]. As many as 75.3% of patients were
treated within 60 minutes in HUS-STEMI I, while the
same target was reached in 62.8% of the HUS-STEMI II
patients (Table 2). Some earlier studies have reported
significant improvement in the door-to-balloon times
over time but the results are from the early years of pri-
mary PCI, when the decrease in delays was more expect-
able [15,16]. More recent studies have shown less
improvement in door-to-balloon times over time. In a
study from a multinational registry GRACE, the door-
to-balloon times remained practically unchanged (75–84
minutes) during the study period from 1999 to 2006
with an exception of the year 1999 when the median
door-to-balloon time was 99 minutes [11]. However, a
recent study of the large CathPCI registry from the USA-hours
HUS-STEMI II
Regular hours Off-hours
p n = 123 n = 178 p
0.972 117 (38–243) 110.5 (48–246) 0.612
0.669 64 (47–89) 68.5 (52–94) 0.270
0.464 40 (29–61) 57.5 (34–87) 0.001
0.945 111 (87–166) 127 (105–182) 0.009
0.597 263.5 (150–407) 290 (189–439) 0.064
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times over the study period: median door-to-balloon
times decreased from 83 min to 67 min and the percent-
age of patients treated within 90 minutes increased from
60% to 83% from 2005 to 2009 [21].
The adherence to recommended time limits was
poorer in other delays than door-to-balloon. The EMS
delay has shrunk over time, but still only 41% of patients
were transported to the PCI hospital in 60 minutes. The
distances in the HUS area are relatively short with about
two thirds of population being gathered in the city of
Helsinki and its suburbs with up to 20–30 km distance
to the Meilahti hospital of HUCH. The longest distances
to the Meilahti hospital are about 100 km.
The median system delay in both datasets was a mi-
nute short of two hours. Only 22% in HUS-STEMI I and
25% in HUS-STEMI II were treated within 90 minutes
(Table 2). The results from a US report from the Na-
tional Registry of Myocardial Infarction from 1999 to
2002 were quite similar showing no substantial improve-
ment in average treatment times: the percentage of pa-
tients with a system delay less than 90 minutes was 35%
in 1999 and increased by 2% in 2002 [12]. Another study
that described the delays in 30 European countries had
median system delays of 60 to 177 minutes [13]. The
system delay of our study is placed just in the middle of
these European results. In our study, the majority of sys-
tem delay is composed of the EMS delay, thus the efforts
to decrease the delays should be focused on EMS.
Patient related delay was quite long in both datasets,
medians being 110 vs. 115 minutes in former vs. later
dataset. This forms almost a half of the total ischemic
time, which is why attempts for reducing this delay
should be established. Public campaigns have been ef-
fective for the recognition of the common symptoms of
a stroke [22,23]; a similar strategy would most probably
increase the awareness of the symptoms and shorten the
delays in the context of AMI.
In a Swedish study, which analyzed the trends in the
treatment of STEMI patients from 1996 to 2007, the
total ischemic times first increased from 185 min to
216 min and then decreased again to 203 min over the
study period. Even the present study demonstrated an
increasing tendency for the delays over time. The total
ischemic times in our study were considerably longer,
246 min and 275 min in HUS-STEMI I and II, respect-
ively. However, further comparison between these stud-
ies is not possible because the Swedish study does not
categorize the different components of the total ischemic
time [14].
Factors associated with delays
Presentation to the hospital during off-hours seemed to
be strongly associated with longer delays in HUS-STEMIII. The difference in door-to-balloon times between
regular and off-hours was 17.5 minutes and, correspond-
ingly, in system delays 16 minutes. During off-hours the
angiography team is on-call so it could be expected that
the delays inside the hospital are longer than in the
regular hours. The results from previous studies asses-
sing the variation in treatment delays between regular
and off-hours are quite similar to our results from HUS-
STEMI II. Reported door-to-balloon times have been
21–25 minutes longer during off- than on-hours [15,16].
Interestingly, hospital presentation time did not affect
the delays in the HUS-STEMI I dataset. The difference
in the impact of off-hours presentation on the in-
hospital delays between the datasets might reflect the
delegation of night-time initial STEMI consultation calls
from interventional cardiologist to the physician in the
coronary care unit in HUCH; this reorganization oc-
curred after the HUS-STEMI I period. The interven-
tional cardiologists participating in the off-hours PCI
procedures were virtually the same during both study
periods and all of them live within 30 minutes from the
hospital.
Patients treated according to the new local guidelines
of antithrombotic medication also had shorter system
and EMS delays. Treatment according to the new guide-
lines did not affect the door-to-balloon time. Therefore,
the new protocol does not seem to cause any additional
delay either inside the hospital or in the EMS.
In HUS-STEMI I, patients who waited for more than
2 hours before contacting the EMS had longer system
delays. This may reflect less specific symptoms in these
patients, which would lengthen the delays in different
steps.
Endpoints
The 90-day mortality and the occurrence of major ad-
verse cardiac event (MACE) in 90 days were similar in
the two datasets. This is expected based on the fact that
there were no significant differences in the system delays
or total ischemic times. The small numerical decrease in
the mortality may reflect development in other treat-
ment for the STEMI patients. Longer system delay was
associated with higher mortality rates in our study which
is in accordance with previous studies [1,3,7].
Medication given prior and/or during the PCI may in-
fluence the mortality [24]. In our data, treatment accord-
ing to new guidelines did not affect 90-day MACE or
mortality.
Strengths and limitations of this study
Both datasets contained all STEMI patients treated with
primary PCI in HUCH during the data collection period.
Thus, the study population represents the true STEMI
population of the HUS area. An observational study
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with delays or the endpoints. Furthermore, there were so
few endpoints that the correlation between the delays
and endpoints could not be analyzed reliably.
Conclusions
Door-to-balloon times have become longer but are still
relatively well within the limits of the European guide-
lines. The EMS delays have become shorter but are still
long in comparison to door-to-balloon times. Arrival at
hospital during off-hours was the only factor clearly as-
sociated with longer delays inside the hospital suggesting
that changes in the hospital strategies during off-hours
should be considered.
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